Evaluation of hepatic function with 13C-methacetin breath test in patients with liver cirrhosis
Rong Wan, Yun-Lin Wu, Hong Wang, Qing Qu, Shu Zhang
Rong Wan, Yun-lin Wu, Qing Qu, Shu Zhang, Department of Gastroenterology, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China
Hong Wang, Department of Gastroenterology, Shanghai Jingan Hospital, Shanghai 200025, China
Correspondence to: Dr. Yun-Lin Wu, Department of Gastroenterology, Ruijin Hospital , Shanghai Second Medical University, Shanghai 200025,China. wanrong1970@163.com
Received: 2004-04-19 Accepted: 2004-05-13
Abstract
AIM: To investigate the characteristics of the 13C-methacetin breath test (13C-MBT) as a tool to monitor hepatic function of patients with liver cirrhosis.
METHODS: Forty-two patients with liver cirrhosis and thirty-one age- and sex-matched healthy controls underwent 13C-MBT. 13C-methacetin (75 mg) was given orally, and the levels of 13CO2 delta over baseline (DOB), metabolisation velocity (MV) and cumulative percentage doses (CD) before and 10, 20, 30, 40, 50, 60, 80, 100 and 120 min after substrate administration breath samples was determined and compared, by non-dispersive infrared spectrometry.
RESULTS: The 13CO2 peak percent doses of healthy controls, Child class A and Child class B patients were 20.3 ±3.5%, 7.5±1.8% or 6.5此新闻共有16页 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
|
